A Study of Lonafarnib With or Without Ritonavir in Patients With HDV
NCT02968641 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL
Last updated 2021-02-16
Summary
A Phase 2b, Open-Label, Randomized Study of the Safety, Tolerability, and Pharmacodynamic Activity of Lonafarnib With or Without Ritonavir in Patients Chronically Infected with Hepatitis Delta Virus
Conditions
- Chronic Delta Hepatitis
Interventions
- DRUG
-
Lonafarnib
antiviral farnesyltransferase inhibitor
- DRUG
-
Ritonavir
CYP 3A4 inhibitor, lonafarnib booster
Sponsors & Collaborators
-
Eiger BioPharmaceuticals
lead INDUSTRY
Principal Investigators
-
Eduardo B Martins, MD, DPhil · Eiger BioPharmaceuticals
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Primary Completion
- 2021-02-12
- FDA Drug
- Yes
More Related Trials
-
Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir Versus Tenofovir Monotherapy in Chronic Hepatitis B
NCT01369212 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate Efficacy and Safety of Peginterferon Alfa-2a (Pegasys) and Adeforvir Dipivoxil (ADV) in Participants With Lamivudine-Resistant Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B
NCT02598063 ·Status: COMPLETED ·Phase: PHASE4
-
Phase Ⅲ Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg-positive Chronic Hepatitis B
NCT02366247 ·Status: UNKNOWN ·Phase: PHASE3
-
Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared With Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients
NCT00402428 ·Status: COMPLETED ·Phase: PHASE3
-
'Tenofovir Pulse and Peg Interferon Alpha 2b' Therapy in HBeAg-positive Patients With Normal ALT
NCT02454764 ·Status: WITHDRAWN ·Phase: NA
-
48 Weeks Combination Therapy for Patients With HBeAg-negative Chronic Hepatitis B Virus (HBV) Infection
NCT00114361 ·Status: COMPLETED ·Phase: PHASE3
-
Phase II Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg Positive Chronic Hepatitis B
NCT02366208 ·Status: COMPLETED ·Phase: PHASE2
-
Myrcludex B in Combination With Peginterferon Alfa-2a Versus Peginterferon Alfa-2a Alone in Patients With Chronic Viral Hepatitis B With Delta-agent
NCT02888106 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Peg-Interferon Alpha-2a Plus Ribavirin in Genotype 1 Chronic Hepatitis C Participants Co-Infected With Human Immunodeficiency Virus
NCT02761629 ·Status: COMPLETED ·Phase: PHASE4
-
PEG-interferon Alfa-2a add-on Study in HBeAg Negative Chronic Hepatitis B Patients
NCT01373684 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Pegylated Interferon Alfa-2a and Lamivudine in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)
NCT01095835 ·Status: COMPLETED ·Phase: PHASE3
-
A Retrospective Biomarker Study of Stored Samples Obtained From Patients With Chronic Hepatitis B
NCT01705704 ·Status: COMPLETED
-
A Study of Peginterferon Alfa-2a (Pegasys) in Participants With Hepatitis B E-Antigen (HBeAg)-Positive Chronic Hepatitis B Virus (HBV)
NCT02604823 ·Status: COMPLETED ·Phase: PHASE4
-
Pharmacokinetic/Pharmacodynamic of Albinterferon Alfa-2b in Chronic Hepatitis B, eAg+, Infection Subjects
NCT00964665 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Study of Peginterferon Alfa-2a With or Without Ribavirin in Participants With Chronic Hepatitis D (CHD)
NCT02731131 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment With Peginterferon Alfa-2a (40 KD) of Chronic Hepatitis B Patients, Who Have Failed Anti-viral Treatment
NCT00226382 ·Status: COMPLETED ·Phase: PHASE4
-
The Investigation of Peginterferon Alfa-2a on Optimal in Chronic Hepatitis B Patients Who Have a High Risk of HCC
NCT03084250 ·Status: UNKNOWN ·Phase: PHASE4
-
A Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B
NCT04846491 ·Status: COMPLETED ·Phase: PHASE3
-
Pegylated Interferon Alpha-2b Monotherapy Versus Combination With Entecavir in HBeAg-negative Chronic Hepatitis B
NCT01243281 ·Status: UNKNOWN ·Phase: NA
-
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis B Who Have Failed Antiviral Treatment With Nucleoside (Nucleotide) Analogues
NCT01794234 ·Status: TERMINATED
-
Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic, Hepatitis B e Antigen-negative Subjects Infected With HBV Virus and Receiving or Stopping Treatment With a NUC Inhibitor
NCT04023721 ·Status: TERMINATED ·Phase: PHASE2
-
HBsAg Seroclearance in Adults With HBV Related Liver Fibrosis After Receiving Combined Therapy of Peg-IFN and Tenofovir.
NCT04640129 ·Status: RECRUITING ·Phase: PHASE4
-
HIDIT II - PegIFN-alfa2a Plus Tenofovir in Chronic Delta Hepatitis
NCT00932971 ·Status: COMPLETED ·Phase: PHASE2
-
HBsAg Loss/Seroconversion in Low Replicative Chronic Hepatitis B Virus(HBV) Infection Patients
NCT02908763 ·Status: UNKNOWN ·Phase: PHASE4
-
A Study of Switch From Nucleotide to Peginterferon Alfa-2a in CHB Patients Achieving HBeAg Loss and HBV DNA <200IU/ml
NCT01464281 ·Status: UNKNOWN ·Phase: NA